Pfizer’s Monthly Obesity Drug Berobenatide Shows Promising Weight Loss-But Can It Compete With Weekly Injectables?
Pfizer’s experimental obesity drug, berobenatide, demonstrates sustained weight loss potential in the mid-stage VESPER-3 clinical trial. Data presented at the American Diabetes Association meeting indicate that monthly dosing maintains efficacy ... Read More